Menu Search
Equities

Fortress Biotech Inc

FBIO:NAQ

Fortress Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.84
  • Today's Change-0.08 / -4.17%
  • Shares traded355.32k
  • 1 Year change-62.83%
  • Beta1.8120
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Fortress Biotech Inc grew revenues 11.58% from 75.74m to 84.51m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -86.58m to -60.64m.
Gross margin68.77%
Net profit margin-130.17%
Operating margin-118.28%
Return on assets-65.90%
Return on equity-272.34%
Return on investment-113.69%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Fortress Biotech Inc fell by 97.59m. Cash Flow from Financing totalled 32.74m or 38.74% of revenues. In addition the company used 128.23m for operations while cash used for investing totalled 2.10m.
Cash flow per share-8.17
Price/Cash flow per share--
Book value per share0.7915
Tangible book value per share-0.0346
More ▼

Balance sheet in USDView more

Fortress Biotech Inc has a Debt to Total Capital ratio of 126.35%, a lower figure than the previous year's 252.97%.
Current ratio1.37
Quick ratio1.24
Total debt/total equity3.92
Total debt/total capital1.26
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.